Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Bill Haddad

8264 posts
Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • General

Prometheus Biosciences Announces Results For PRA023 In Both ARTEMIS-UC Phase 2 And APOLLO-CD Phase 2a Studies; ARTEMIS-UC Met Primary Endpoint

By Bill Haddad
Today, 12:49 PM
SAN DIEGO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and

RXDX

Read More
2 minute read
  • Biotech
  • General

Replimune Enters Clinical Collaboration Agreement With Roche For Development Of RP3 In Colorectal Cancer And Hepatocellular Carcinoma

By Bill Haddad
Today, 12:49 PM
P3 will be developed in combination with atezolizumab and bevacizumab for the third-line treatment of colorectal cancer (CRC) and for the first- and second-line treatment of hepatocellular carcinoma

REPL

Read More
1 minute read
  • Guidance
  • News

Lowe’s Affirms 2022 Outlook, Sees FY22 Total Sales $97B-$98B., Sees Adj. EPS $13.65-$13.80

By Bill Haddad
Today, 12:49 PM
Full Year 2022 Outlook -- a 53-week year (comparisons to full year 2021 –a 52-week year) Total sales of approximately $97 to $98 billion, including the 53rd week 53rd week expected to

LOW

Read More
1 minute read
  • General
  • Politics

AP Projects Sen. Warnock Victory In GA Runoff Election

By Bill Haddad
Today, 12:49 PM
https://apnews.com/article/2022-midterm-elections-walker-warnock-runoff-3d4e4d1ab1760792454e1cbd618ce332

SPY

Read More
1 minute read
  • News

Doma Holdings To Reduce 40% Of Workforce, Expects $9M-$10M In Employment Related Charges And Estimates Annualized Compensation Expense Savings Of $85M-$90M

By Bill Haddad
Today, 12:49 PM
On December 6, 2022, Doma Holdings, Inc. (the “Company”) committed to implementing a strategic initiative and corresponding reduction in workforce (the "Reduction Plan"), designed to reduce costs,On December 6, 2022, Doma Holdings, Inc.

DOMA

Read More
1 minute read
  • News

Goldman Sachs CEO Solomon Says Cautious About Macro Outlook, Says Clients Are Taking Risk Down

By Bill Haddad
Today, 12:49 PM
-Reuters

GS

Read More
1 minute read
  • Earnings
  • News

Couchbase Q3 Adj. EPS $(0.22) Beats $(0.33) Estimate, Sales $38.60M Beat $36.65M Estimate

By Bill Haddad
Today, 12:49 PM
Couchbase (NASDAQ:BASE) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.33) by 33.33 percent. This is a 24.14 percent increase over losses of $(0.29) per share from the

BASE

Read More
1 minute read
  • Earnings
  • News

AutoZone Q1 EPS $27.45 Beats $25.27 Estimate, Sales $3.98B Beat $3.86B Estimate

By Bill Haddad
Today, 12:49 PM
AutoZone (NYSE:AZO) reported quarterly earnings of $27.45 per share which beat the analyst consensus estimate of $25.27 by 8.63 percent. This is a 6.85 percent increase over earnings of $25.69 per share from the same

AZO

Read More
1 minute read
  • Earnings
  • News

Signet Jewelers Q3 Adj. EPS $0.74 Beats $0.31 Estimate, Sales $1.58B Beat $1.50B Estimate

By Bill Haddad
Today, 12:49 PM
Signet Jewelers (NYSE:SIG) reported quarterly earnings of $0.74 per share which beat the analyst consensus estimate of $0.31 by 138.71 percent. This is a 48.25 percent decrease over earnings of $1.43 per share from the

SIG

Read More
1 minute read
  • Events
  • News

Southwest Airlines Co. 2022 Investor Day Dec. 7 At 12:00 p.m. ET

By Bill Haddad
Today, 12:49 PM
Date: Wednesday, December 7, 2022     Time: 12:00 p.m. ET     Speakers: Bob

LUV

Posts navigation

Previous 1 … 34 35 36 … 827 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service